ALCON AG

NYSE: ALC (Alcon Inc.)

Kemas kini terakhir: 02 Jan, 9:59PM

77.60

-1.21 (-1.54%)

Penutupan Terdahulu 78.81
Buka 78.90
Jumlah Dagangan 1,310,869
Purata Dagangan (3B) 1,899,898
Modal Pasaran 38,263,422,976
Harga / Pendapatan (P/E TTM) 37.67
Harga / Pendapatan (P/E Ke hadapan) 23.20
Harga / Jualan (P/S) 3.86
Harga / Buku (P/B) 1.68
Julat 52 Minggu
71.55 (-7%) — 99.20 (27%)
Tarikh Pendapatan 11 Nov 2025
Hasil Dividen (DY TTM) 0.35%
Margin Keuntungan 11.28%
Margin Operasi (TTM) 13.30%
EPS Cair (TTM) 2.25
Pertumbuhan Hasil Suku Tahunan (YOY) 0.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 41.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.63%
Nisbah Semasa (MRQ) 2.70
Aliran Tunai Operasi (OCF TTM) 2.12 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 1.18 B
Pulangan Atas Aset (ROA TTM) 2.74%
Pulangan Atas Ekuiti (ROE TTM) 5.23%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Menaik Bercampur
Medical Instruments & Supplies (Global) Menaik Bercampur
Stok Alcon Inc. Menurun Menurun

AISkor Stockmoo

0.8
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga 3.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.5
Purata 0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALC 38 B 0.35% 37.67 1.68
RMD 37 B 0.21% 25.71 6.18
STVN 5 B 0.21% 32.37 3.23
BDX 59 B 0.50% 35.43 2.32
WST 20 B 0.15% 41.01 6.12
BLCO 6 B - - 0.940

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.13%
% Dimiliki oleh Institusi 68.26%
Julat 52 Minggu
71.55 (-7%) — 99.20 (27%)
Julat Harga Sasaran
75.00 (-3%) — 100.00 (28%)
Tinggi 100.00 (Mizuho, 28.87%) Beli
Median 94.50 (21.78%)
Rendah 75.00 (B of A Securities, -3.35%) Jual
Purata 90.33 (16.41%)
Jumlah 4 Beli, 1 Pegang, 1 Jual
Harga Purata @ Panggilan 78.43
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Stifel 09 Jan 2026 80.00 (3.09%) Pegang 80.13
B of A Securities 11 Dec 2025 75.00 (-3.35%) Jual 78.76
BTIG 24 Nov 2025 91.00 (17.27%) Beli 76.25
Baird 13 Nov 2025 98.00 (26.29%) Beli 78.61
Needham 12 Nov 2025 98.00 (26.29%) Beli 79.44
Mizuho 11 Nov 2025 100.00 (28.87%) Beli 77.36

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
06 Jan 2026 Pengumuman Alcon Terminates Agreement to Acquire STAAR Surgical
06 Jan 2026 Pengumuman Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
30 Dec 2025 Pengumuman Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
19 Dec 2025 Pengumuman Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
19 Dec 2025 Pengumuman Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
17 Dec 2025 Pengumuman STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
17 Dec 2025 Pengumuman Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
17 Dec 2025 Pengumuman Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
16 Dec 2025 Pengumuman Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
16 Dec 2025 Pengumuman Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
12 Dec 2025 Pengumuman Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
11 Dec 2025 Pengumuman STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
11 Dec 2025 Pengumuman Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
10 Dec 2025 Pengumuman Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
09 Dec 2025 Pengumuman Alcon Announces Amended Merger Agreement with STAAR Surgical
09 Dec 2025 Pengumuman Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
08 Dec 2025 Pengumuman Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
08 Dec 2025 Pengumuman Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
08 Dec 2025 Pengumuman STAAR Surgical Announces Expiration of Go-Shop Period
02 Dec 2025 Pengumuman Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
11 Nov 2025 Pengumuman Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
10 Nov 2025 Pengumuman Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 Pengumuman STAAR Surgical Announces Amendments to Alcon Merger Agreement
04 Nov 2025 Pengumuman Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
04 Nov 2025 Pengumuman Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
31 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
27 Oct 2025 Pengumuman STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
24 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
24 Oct 2025 Pengumuman Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
23 Oct 2025 Pengumuman Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
Papar semua
Hasil Dividen (DY TTM) 0.35%
Purata Hasil Dividen 5T 0.20%
Nisbah Pembayaran 11.81%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 May 2024 08 Apr 2024 16 May 2024 0.2644 Tunai
10 May 2023 30 Mar 2023 12 May 2023 0.2356 Tunai
29 Apr 2022 24 Mar 2022 05 May 2022 0.2083 Tunai
04 May 2021 24 Mar 2021 06 May 2021 0.0909 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 0.264 1 0.31
2023 0.236 1 0.30
2022 0.208 1 0.30
2021 0.091 1 0.10

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda